Data / Drug companies / Oxcarbazepine
Oxcarbazepine: 46 companies and 129 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Oxcarbazepine is listed in the FDA National Drug Code Directory by 46 companies, with 129 products in commercial distribution. 122 of the products (94.6%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet, film coated; suspension; tablet, and the newest product started marketing on October 16, 2026.
The request: Get every company that lists oxcarbazepine in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 46
- Products
- 129
- Generic (ANDA) products
- 122 (94.6%)
- Application numbers
- 27
- Routes
- Oral
- Brand names
- Trileptal, Oxtellar XR
- openFDA record search
- api.fda.gov
Companies that list oxcarbazepine
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Remedyrepack Inc. | 13 | tablet, film coated | Generic drugs (ANDA) | May 20, 2026 |
| Advagen Pharma Ltd | 7 | tablet; tablet, film coated | Generic drugs (ANDA) | May 20, 2025 |
| Breckenridge Pharmaceutical, Inc. | 6 | tablet, film coated | Generic drugs (ANDA) | January 11, 2008 |
| Major Pharmaceuticals | 6 | tablet, film coated | Generic drugs (ANDA) | April 3, 2026 |
| Coupler LLC | 5 | tablet, film coated | Generic drugs (ANDA) | May 6, 2026 |
| Camber Pharmaceuticals, Inc. | 4 | tablet, film coated; suspension | Generic drugs (ANDA) | October 20, 2023 |
| Cardinal Health 107, LLC | 4 | tablet, film coated | Generic drugs (ANDA) | January 24, 2023 |
| Novartis Pharmaceuticals Corporation | 4 | tablet, film coated; suspension | New drug applications (NDA) | May 30, 2001 |
| Ajanta Pharma USA Inc. | 3 | tablet, extended release | Generic drugs (ANDA) | February 22, 2024 |
| American Health Packaging | 3 | tablet, film coated | Generic drugs (ANDA) | February 2, 2023 |
| Ani Pharmaceuticals, Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | July 15, 2025 |
| Apotex Corp. | 3 | tablet, extended release | Generic drugs (ANDA) | September 3, 2024 |
| Aurobindo Pharma Limited | 3 | tablet, film coated, extended release | Generic drugs (ANDA) | October 16, 2026 |
| AvPAK | 3 | tablet, film coated | Generic drugs (ANDA) | June 7, 2023 |
| Bryant Ranch Prepack | 3 | tablet, film coated | Generic drugs (ANDA) | January 11, 2008 |
| Bryant Ranch Prepack | 3 | suspension; tablet, film coated | Generic drugs (ANDA) | May 1, 2025 |
| Glenmark Pharmaceuticals Inc., USA | 3 | tablet, film coated | Generic drugs (ANDA) | October 9, 2007 |
| Golden State Medical Supply, Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | January 11, 2008 |
| Ingenus Pharmaceuticals, LLC | 3 | tablet, extended release | Generic drugs (ANDA) | June 1, 2025 |
| NCS HealthCare of Ky, LLC DBA Vangard Labs | 3 | tablet, film coated | Generic drugs (ANDA) | July 15, 2025 |
| NorthStar RxLLC | 3 | tablet, film coated; suspension | Generic drugs (ANDA) | September 1, 2024 |
| Sun Pharmaceutical Industries, Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | October 9, 2007 |
| Supernus Pharmaceuticals, Inc. | 3 | tablet | New drug applications (NDA) | January 17, 2013 |
| Umedica Laboratories USA Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | January 1, 2026 |
| XLCare Pharmaceuticals, Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | July 18, 2024 |
| Zameer Pharmaceuticals LLC | 3 | tablet, film coated | Generic drugs (ANDA) | July 6, 2026 |
| Zydus Lifesciences Limited | 3 | tablet | Generic drugs (ANDA) | July 10, 2025 |
| Zydus Pharmaceuticals USA Inc. | 3 | tablet | Generic drugs (ANDA) | July 10, 2025 |
| Bryant Ranch Prepack | 2 | tablet, film coated | Generic drugs (ANDA) | January 11, 2022 |
| Direct_Rx | 2 | tablet, film coated | Generic drugs (ANDA) | September 9, 2024 |
| Amneal Pharmaceuticals LLC | 1 | suspension | Generic drugs (ANDA) | June 4, 2012 |
| Ascend Laboratories, LLC | 1 | suspension | Generic drugs (ANDA) | January 1, 2020 |
| Asclemed USA Inc. | 1 | tablet, film coated | Generic drugs (ANDA) | January 11, 2022 |
| Biocon Pharma Inc. | 1 | suspension | Generic drugs (ANDA) | May 31, 2024 |
| Bionpharma Inc. | 1 | suspension | Generic drugs (ANDA) | February 14, 2023 |
| Chartwell Governmental & Specialty RX, LLC. | 1 | suspension | Generic drugs (ANDA) | September 21, 2021 |
| Chartwell RX, LLC | 1 | suspension | Generic drugs (ANDA) | September 21, 2021 |
| Epic Pharma, LLC | 1 | suspension | Generic drugs (ANDA) | January 30, 2023 |
| Kanchan Healthcare Inc | 1 | suspension | Generic drugs (ANDA) | May 1, 2025 |
| Macleods Pharmaceuticals Limited | 1 | for suspension | Generic drugs (ANDA) | July 11, 2025 |
| Marlex Pharmaceuticals, Inc. | 1 | suspension | Generic drugs (ANDA) | May 1, 2025 |
| Novadoz Pharmaceuticals LLC | 1 | suspension | Generic drugs (ANDA) | May 29, 2026 |
| Precision Dose, Inc. | 1 | suspension | Generic drugs (ANDA) | September 13, 2017 |
| Preferred Pharmaceuticals Inc. | 1 | tablet, film coated | Generic drugs (ANDA) | February 15, 2021 |
| Proficient Rx LP | 1 | tablet, film coated | Generic drugs (ANDA) | October 9, 2007 |
| Proficient Rx LP | 1 | tablet, film coated | Generic drugs (ANDA) | January 11, 2022 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 87 | 67.4% |
| Suspension | 17 | 13.2% |
| Tablet | 12 | 9.3% |
| Tablet, extended release | 9 | 7% |
| Tablet, film coated, extended release | 3 | 2.3% |
| For suspension | 1 | 0.8% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 122 | 94.6% |
| New drug applications (NDA) | 7 | 5.4% |
Pharmacologic classes
| Class | Products |
|---|---|
| Anti-epileptic Agent | 129 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.